Arrowhead Pharmaceuticals develops and commercializes RNA interference medicines that silence genes associated with intractable diseases. The company’s TRiM™ platform is used to design targeted RNAi therapeutics for tissues including liver, lung, muscle, adipose and central nervous system tissue.
Recurring ARWR news covers REDEMPLO® (plozasiran), an siRNA medicine approved in the United States and Australia as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. Company updates also address plozasiran data across hypertriglyceridemia, regulatory actions in additional geographies, pricing and market-access strategy, fiscal results, investor events, and clinical or partnering developments involving programs such as ARO-PNPLA3, ARO-INHBE and ARO-ALK7.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) licensed ARO-PNPLA3 to Madrigal Pharmaceuticals in an exclusive global agreement announced May 5, 2026. Phase 1 data published in The New England Journal of Medicine showed up to 46% liver fat reduction in PNPLA3 I148M homozygous patients.
Financial terms: $25 million upfront, up to $975 million in milestones, and tiered royalties in the high-single digits to mid-teens.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced participation in multiple investor and scientific events across May 2026, including BofA Healthcare (May 12-14), TIDES USA (May 11-14), ECO 2026 (May 12-15), RBC Capital Markets (May 19-20), EAS 2026 (May 24-27) and EASL 2026 (May 27-30).
Presentations cover RNAi therapeutics, MAPT/tau suppression, activin E and metabolic dysfunction, plozasiran clinical data, and ARO-INHBE liver-fat results. Materials and webcasts will be available on the company Events and Presentations investor page.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced TGA approval of REDEMPLO (plozasiran) in Australia for adult patients with familial chylomicronemia syndrome (FCS) whose standard triglyceride‑lowering therapies were inadequate. REDEMPLO is the first approved FCS medicine in Australia and is given subcutaneously once every three months.
The approval cites Phase 3 PALISADE data showing a median 80% triglyceride reduction with 25 mg and an 83% lower odds of acute pancreatitis in pooled dose groups versus placebo; common adverse reactions include hyperglycaemia (12.8%).
Arrowhead Pharmaceuticals (NASDAQ: ARWR) received a positive CHMP opinion recommending approval of REDEMPLO (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). The CHMP based its opinion on Phase 3 PALISADE data showing a median 80% triglyceride reduction and fewer acute pancreatitis cases versus placebo. The European Commission decision is expected in Q2 2026; REDEMPLO is self-administered subcutaneously every three months and carries known adverse reactions including hyperglycaemia (12.8%).
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will webcast its fiscal 2026 second quarter results on May 7, 2026 at 4:30 p.m. ET. The company will host a live audio webcast and conference call to discuss results for the quarter ended March 31, 2026.
Investors can access the live webcast on Arrowhead's Events and Presentations page; a replay will be available about two hours after the call. Analysts must register to receive dial-in details and a personalized PIN to join the conference call.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported two-year open-label extension data for plozasiran in hypertriglyceridemia presented at ACC.26 on March 28, 2026. Patients with severe HTG saw a median -83% triglyceride reduction; 96% achieved TG <500 mg/dL. No adjudicated acute pancreatitis events occurred across the 2-year OLE.
Durable reductions were also observed in remnant cholesterol, non-HDL cholesterol, and ApoB with a safety profile consistent with earlier trials.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced participation in multiple investor events in March 2026, including TD Cowen, Leerink, Jefferies Biotech on the Beach, and Barclays conferences.
Scheduled appearances include fireside chats, investor dinners, and 1x1 meetings between March 2–11, 2026; presentation materials and webcasts will be posted on the company's Investors Events and Presentations page.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported fiscal 2026 first quarter results for the period ended December 31, 2025, and hosted a conference call on February 5, 2026. Key developments include FDA approval and U.S. launch of REDEMPLO for familial chylomicronemia syndrome, additional approvals in China and Canada, initiation of multiple Phase 1/2a trials, encouraging obesity interim data, and strengthened liquidity from concurrent public offerings.
Selected financials: Revenue $264.0M, operating income $40.8M, net income attributable to Arrowhead $30.8M, total cash resources $916.6M, and proceeds of $930.0M from public financings.
ADT (NYSE: ADT) will join the S&P SmallCap 600 effective prior to the opening of trading on Feb 9, 2026, as part of index changes by S&P Dow Jones Indices. The rebalancing also adds Ciena (CIEN) to the S&P 500 and moves Arrowhead Pharmaceuticals (ARWR) into the S&P MidCap 400 on Feb 9; OneSpaWorld (OSW) joins the SmallCap 600 on Feb 10.
Dayforce was removed following an acquisition by Thoma Bravo, and Dynavax was deleted ahead of its pending acquisition by Sanofi.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has dosed the first subjects in a Phase 1/2a study of ARO-DIMER-PA, described as the first clinical RNAi candidate designed to silence two genes with one molecule (PCSK9 and APOC3) using Arrowhead's TRiM™ platform. Preclinical data in hyperlipidemic nonhuman primates showed potent lowering of PCSK9 and APOC3 and reductions in non-HDL cholesterol, LDL-C, and triglycerides. The study advances Arrowhead's cardiometabolic RNAi portfolio alongside approved REDEMPLO and ongoing programs.